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Abstract
Background: Genetic studies associated the CAPB locus with familial risk of brain and prostate cancers. We have identified
HSPG2 (Perlecan) as a candidate gene for CAPB. Previously we have linked Perlecan to Hedgehog signaling in Drosophila. More
recently, we have demonstrated the importance of Hedgehog signaling in humans for advanced prostate cancer.
Results: Here we demonstrate Perlecan expression in prostate cancer, and its function in prostate cancer cell growth through
interaction and modulation of Sonic Hedgehog (SHH) signaling. Perlecan expression in prostate cancer tissues correlates with a
high Gleason score and rapid cell proliferation. Perlecan is highly expressed in prostate cancer cell lines, including androgen
insensitive cell lines and cell lines selected for metastatic properties. Inhibition of Perlecan expression in these cell lines decreases
cell growth. Simultaneous blockade of Perlecan expression and androgen signaling in the androgen-sensitive cell line LNCaP was
additive, indicating the independence of these two pathways. Perlecan expression correlates with SHH in tumor tissue
microarrays and increased tumor cell proliferation based on Ki-67 immunohistochemistry. Inhibition of Perlecan expression by
siRNA in prostate cancer cell lines decreases SHH signaling while expression of the downstream SHH effector GLI1 rescues the
proliferation defect. Perlecan forms complexes with increasing amounts of SHH that correlate with increasing metastatic
potential of the prostate cancer cell line. SHH signaling also increases in the more metastatic cell lines. Metastatic prostate cancer
cell lines grown under serum-starved conditions (low androgen and growth factors) resulted in maintenance of Perlecan
expression. Under low androgen, low growth factor conditions, Perlecan expression level correlates with the ability of the cells
to maintain SHH signaling.
Conclusion: We have demonstrated that Perlecan, a candidate gene for the CAPB locus, is a new component of the SHH
pathway in prostate tumors and works independently of androgen signaling. In metastatic tumor cells increased SHH signaling
correlates with the maintenance of Perlecan expression and more Perlecan-SHH complexes. Perlecan is a proteoglycan that
regulates extracellular and stromal accessibility to growth factors such as SHH, thus allowing for the maintenance of SHH
signaling under growth factor limiting conditions. This proteoglycan represents an important central regulator of SHH activity
and presents an ideal drug target for blocking SHH effects.
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Genetic mapping studies for familial prostate cancer have
identified numerous chromosomal regions linked to
prostate cancer susceptibility. On chromosome one a
genetic association has been demonstrated between clini-
cally significant prostate cancer and the brain tumor
glioblastoma multiforme at 1p36 (CArcinoma Prostate
Brain, CAPB), suggesting the presence of a common onco-
gene for these tumors [1-3]. Using bioinformatics based
analysis of text mining and gene expression data we have
identified candidate genes within the CAPB locus. One of
these genes is HSPG2 (Perlecan). Perlecan is a heparan
sulfate proteoglycan that is secreted into the extracellular
matrix and can bind growth factors [4]. Thus Perlecan can
act as a reservoir or modulator of growth factor function.
One growth factor associated with Perlecan is Hedgehog
[5]. Sonic Hedgehog signaling has recently been shown to
be critical for cancer growth and metastasis in multiple
tumor types [6]. In a large proportion of prostate cancers
high levels of Sonic Hedgehog expression is observed along
with expression of multiple members of the Hedgehog
signaling pathway such as its receptor Patched1, down-
stream transcription factor Gli1, and intracellular modula-
tor Hedgehog Interacting Protein [7,8]. Activation of the
Hedgehog pathway has been detected in metastatic pros-
tate tumors [8,9], and higher levels of pathway activity are
associated with the metastatic phenotype [9]. Blocking the
Sonic Hedgehog pathway with cyclopamine inhibits pro-
liferation of prostate cancer cell lines [7-9] and primary
prostate tumor cell cultures [7]. Treatment of mice with
cyclopamine results in the inhibition of tumor xenograft
growth in multiple tumor types, including prostate
tumors [7,10]. Our bioinformatics analyses [6,7] sug-
gested that genes encoding two components of the Sonic
Hedgehog pathway, Suppressor of Fused (Su(fu)) and
Smoothened, the target of cyclopamine, lie in chromo-
somal regions implicated in familial prostate cancer
[11,12]. Su(fu) is a negative regulator of pathway activity,
thus loss of Su(fu) function would increase Sonic Hedge-
hog activity. Molecular analyses of prostate tumors
revealed that Su(fu) protein is absent in most highly
aggressive tumors and somatic truncation mutations in
the Su(fu) gene have been identified [8] consistent with
the hypothesis that Su(fu) would act as a prostate tumor
suppressor gene by inhibiting Sonic Hedgehog signaling.
These studies demonstrate the critical nature of Sonic
Hedgehog signaling in tumorigenesis and metastasis.
Thus identification of additional mechanisms for the reg-
ulation of Sonic Hedgehog signaling in cancer takes on
added importance. Here we demonstrate that expression
of the candidate CAPB gene HSPG2 (Perlecan) is present in
prostate cancers, up-regulated in aggressive prostate can-
cers and under poor cell growth conditions, and regulates
prostate cancer cell proliferation. In addition, we demon-
strate that Perlecan's effects on cell growth are independ-
ent of androgen signaling and occur through the binding
of Sonic Hedgehog, resulting in modulation of the Sonic
Hedgehog-Patched-Gli signaling pathway. This data,
along with data linking Perlecan to metastatic tumor envi-
ronments such a bone matrix [13], presents a general
model in which Perlecan expression by tumor cells under
poor growth conditions enhances their ability to utilize
growth factors until their spread to suitable metastatic
tumor microenvironments for accelerated growth.
Results
Perlecan is expressed in and associated with aggressive 
prostate cancers
After identification of Perlecan as a candidate gene for the
CAPB locus we sought to confirm the presence of Perlecan
in primary prostate cancers. Immunohistochemical anal-
ysis for Perlecan in prostate cancer tissue microarrays with
600 patient samples demonstrated that Perlecan, a
secreted proteoglycan, is present in the lumens of 54% of
malignant prostate cancer glands, but not in normal
glands (Figure. 1A–D, Table 1). There was a significant
increase in Perlecan levels in invasive tumors compared to
either benign prostate tissue or the precancerous lesion
high grade prostatic intraepithelial neoplasia (HGPIN). In
particular Perlecan expression was associated with more
aggressive tumors, as evidenced by their higher Gleason
score (Gleason score 7,8,9 versus Gleason score 5 and 6
tumors). Perlecan expression was also significantly associ-
ated with increased prostate cancer cell proliferation, as
demonstrated by Ki-67 (PCNA) immunohistochemical
staining (Table 1). To extend the evaluation of Perlecan
we examined Perlecan RNA (Figure 1G) and/or protein
(Figure 1H) levels in matched benign and tumor samples
from 10 individual patients. At the RNA level Perlecan was
significantly increased in four out of six matched patient
tumor and benign prostate samples. Perlecan protein was
upregulated in two of four additional patient samples
where protein was examined. An examination of the
Gleason score for the primary tumor samples revealed
that the only Gleason score 8 tumor upregulated Perlecan.
These findings correlate with the results from the tissue
microarrays (Table 1). Perlecan Ki-67 staining was also
evaluated in five of the patient samples, two with low Per-
lecan, and three with increased Perlecan expression.
Immunoblotting demonstrated a direct correlation
between increased Perlecan expression and increased Ki-
67 levels. These findings matched the immunohistochem-
ical staining results from the tissue microarrays (Table 1).
We also examined Perlecan protein expression on tissue
microarray samples from patients with primary and met-
astatic prostate cancer identified at autopsy. In these sam-
ples Perlecan expression was upregulated in the primary
prostate tumor and metastatic prostate cancer that had
spread to the lungs and liver (Figure 1E, Table 1). Perlecan
expression was lower in tumor present in lymph nodes orPage 2 of 15
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Perlecan protein levels in human prostate tumorsFigure 1
Perlecan protein levels in human prostate tumors. Immunohistochemistry of Perlecan protein in prostate cancer (A) 
and normal prostate (B). Perlecan is present as a secreted protein in the tumor gland lumens (C) but not in the lumens of 
benign glands or benign corpora amylacea secretions (D). Staining is also seen in metastatic prostate cancer specimens (E). Sec-
ondary antibody alone control fails to demonstrate staining (F). All images originally photographed at 400 × magnification. 
Quantitation of Perlecan mRNA expression by Real Time PCR (G) or protein by digitized dot blot (H) in normal prostate and 
tumor samples from individual patients presented as fold change in tumor versus normal. Gleason scores for the tumors are 
listed. Red numbers or columns indicate patients previously shown to have increased expression of SHH, PTCH1 and GLI1 [7].
Molecular Cancer 2006, 5:9 http://www.molecular-cancer.com/content/5/1/9soft tissue metastasis, indicating site specific differences in
Perlecan expression in metastatic prostate cancer.
Basal Perlecan expression is highest in an androgen 
sensitive tumor cell line
Baseline expression of Perlecan was examined in the met-
astatic prostate cancer cell lines LNCaP, DU-145, and
PC3. Using analysis of spotted cDNA microarray expres-
sion data [14] quantitative Real Time PCR and immunob-
lotting, Perlecan expression was found in all three cell lines
with the highest levels present in the androgen sensitive
LNCaP cell line (Figure 2A). We extended these findings
by examining Perlecan expression with respect to tumor
cell invasion and metastasis in an LNCaP tumor progres-
sion model. The LNCaP-derived cell line series (LNCaP,
C4, C4-2, C4-2B) were derived from serial passage
through nude mice [15,16]. The androgen sensitive paren-
tal LNCaP line is incapable of forming tumors in nude
mice without stromal cell support. The C4 subline will
form tumors when injected into castrated males, indicat-
ing that it is androgen insensitive, but will not metasta-
size. C4-2 is an androgen insensitive line that will
metastasize, and the C4-2B subline is an androgen insen-
sitive line that rapidly forms bone metastases. When Per-
lecan expression was assayed in the LNCaP series (Figure
2A) Perlecan RNA and protein was present in all the pros-
tate cancer cell lines at levels lower than the androgen sen-
sitive LNCaP cells. Thus all the androgen insensitive
prostate cancer cell lines expressed lower levels of Perle-
can RNA than he androgen sensitive cell line.
Inhibition of Perlecan decreases prostate cancer cell 
proliferation in androgen sensitive and androgen 
insensitive tumor cells
To examine the direct effect of Perlecan on cancer cell
growth we examined the ability of small interference RNA
Table 1: Immunohistochemical Staining for Perlecan and Co-Localization with Ki-67.
Perlecan Negative Perlecan Positive
Histology Tumor 170 203
Normal 211 31 p < 0.00005
Tumor 170 203
HGPIN 46 7 p < 0.00005
Clinical Stage cT2 11 12
cT3/4 2 3 N.S.
Tumor Grade Gleason 6 26 5
Gleason 7,8,9 38 23 p = 0.0335
Pathologic Stage pT1-pT2 35 17
pT3 29 11 N.S.
Nodal Status pN0 18 23
pN1 0 1 N.S.
Outcomes PSA Recurrence 4 5
No PSA Recurrence 13 22 N.S.
Vital Status Alive 26 36
Dead 2 5 N.S.
Perlecan Expression in Metastasis
Metastatic Site Perlecan Negative Perlecan Positive P value vs. Prostate
Primary Tumor (Prostate) 3 24
Lymph Node 8 9 p = 0.0073
Soft Tissue 15 18 p = 0.0039
Liver 5 23 p = 0.4781
Lung 3 24 p = 1.000
Association of Ki-67 (PCNA) Staining with Perlecan Staining
Sample Staining Number of Samples Mean % of Ki-67 
positivity
Two-tailed ANOVA
Perlecan positive 143 6.715278 p = 0.0478
Perlecan negative 214 5.028571
* Tumor grade is presented as Gleason score. Pathologic staging uses the American Joint Commission on Cancer (AJCC) 2002 tumor staging 
criteria. HGPIN = high grade prostatic intraepithelial neoplasia.Page 4 of 15
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Perlecan expression and functional analysis in cell linesFigure 2
Perlecan expression and functional analysis in cell lines. A. Relative Perlecan mRNA levels from Realtime PCR (LNCaP 
series) and spotted cDNA microarray data (LNCaP, DU145, PC3). All samples presented normalized to LNCaP at 100%. 
Androgen sensitive: LNCaP. Androgen insensitive: C4, C4-2, C4-2B, PC3, DU145. B. Inhibition by Perlecan siRNA decreases 
prostate cancer cell proliferation. BrdU incorporation in the LNCaP, C4, C4-2 and C4-2B cell lines. All samples were normal-
ized to control (scrambled siRNA treated) cells at 100%. Black bars represent control samples transfected with scrambled 
siRNA. Grey bars represent samples transfected with Perlecan siRNA. Error bars represent n = 3 independent samples. C. 
Additive effect of Perlecan siRNA and androgen blockade on cell proliferation. BrdU incorporation in LNCaP cells after Perle-
can siRNA and/or bicalutimide (Casodex) treatment. Control and Casodex alone samples were treated with a scrambled 
siRNA. p < 0.0001 for comparisons between groups. Error bars represent n = 6 for independent transfections.
Molecular Cancer 2006, 5:9 http://www.molecular-cancer.com/content/5/1/9(siRNA) directed at Perlecan message to inhibit cell growth
in the increasingly metastatic LNCaP cell line series
LNCaP, C4, C4-2 and C4-2B. Proliferation assays demon-
strated approximately equal decreases in BrdU incorpora-
tion for each cell line (Figure 2B). To evaluate the
relationship between Perlecan and androgens on cancer
cell growth we performed BrdU incorporation studies on
the androgen sensitive LNCaP cells utilizing androgen
blockade with bicalutimide (Casodex) with Perlecan
siRNA or a scrambled siRNA control (Figure 2C). Inde-
pendent application of Perlecan siRNA or androgen block-
ade resulted in 28% and 45% decreases in BrdU
Co-localization of Shh and Perlecan, and correlation with Ki-67 stainingFigure 3
Co-localization of Shh and Perlecan, and correlation with Ki-67 staining. Immunohistochemistry for Sonic Hedgehog 
(A), demonstrating both weak cytoplasmic staining in prostate cancer epithelial cells and stronger intraluminal staining of 
secreted SHH. Co-localization of Perlecan (B) and Sonic Hedgehog (C) in consecutive sections of prostate carcinoma. Exam-
ples of co-localization of the secreted proteins in gland lumens are highlighted (red asterisks). All histologic images originally 
photographed at 400 × magnification. Significant co-localization of Perlecan and SHH staining was associated with higher cellu-
lar proliferation rates as indicated by Ki-67 nuclear staining by immunohistochemistry (D).Page 6 of 15
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siRNA and androgen blockade resulted in an additive
effect with a 62% reduction.
Perlecan correlates with Sonic Hedgehog expression
Since androgen signaling and Perlecan effects on tumor
cell proliferation are independent, we asked what other
signaling pathway Perlecan might be modulating to sup-
port prostate cancer cell growth. We and others have
recently shown that Sonic Hedgehog regulates prostate
cancer cell growth [6-9,17]. Since Perlecan has been impli-
cated in Hedgehog signaling in Drosophila [5], we exam-
ined the correlation and interaction of Perlecan with
Sonic Hedgehog in prostate cancer samples. Using
Perlecan and the SHH-GLI1 pathwayFigure 4
Perlecan and the SHH-GLI1 pathway. A. Decreased Perlecan and SHH signaling in Perlecan RNAi treated LNCaP cells. 
Expression of Perlecan, and the SHH signaling molecules PTCH1 and GLI1 as determined by Real Time PCR. Black columns rep-
resent control samples, Grey columns represent Perlecan RNAi treated cells. All expression normalized to β-actin levels. Real 
Time PCR studies were run with an n = 9. Error bars indicate standard deviation. B. Gli-1 transfection restores BrdU Prolifer-
ation in Perlecan RNAi treated cells. Percent BrdU incorporation normalized to levels of BrdU incorporation in control 
(scrambled RNAi treated) cells. BrdU analysis was done with n = 6. Error bars indicate standard deviation. C. Immunoprecipi-
tation with anti-Perlecan antibody pulls down SHH. Co-immunoprecipitation of SHH and Perlecan from equal amounts of 
medium conditioned by 80% confluent cells. Size marker is indicated. Due to modifications, mature SHH runs as an approxi-
mately 22 kD band. Note the increased amount of bound SHH in the C4-2 and C4-2B cell lines. D. Relative expression of the 
SHH pathway components in LNCaP series cells. Black columns represent SHH mRNA, grey columns represent PTCH 
mRNA, with expression presented as ratios with respect to expression in LNCaP cells. While SHH is lower, PTCH is higher in 
the androgen insensitive metastatic cell lines C4-2 and C4-2B compared to LNCaP. All mRNAs by QRT-PCR were normalized 
to Beta-actin.Page 7 of 15
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Perlecan function under androgen and growth factor limitationFigure 5
Perlecan function under androgen and growth factor limitation. A. Minimal changes in Perlecan mRNA levels in 
LNCaP-derived cell lines upon serum starvation. RealTime PCR analysis of Perlecan mRNA levels presented as fold increase in 
Perlecan under normal (black bars) or starved (grey bars) growth conditions. While Perlecan mRNA is decreased in LNCaP, all 
other cell lines demonstrate no change in Perlecan mRNA levels. B. Top Panel: No change in Perlecan protein levels upon 
serum starvation. Agarose based western blots from protein extracts derived from exponentially growing or serum starved 
LNCaP, C4, C4-2, and C4-2B cells. No significant differences are noted in protein levels between the cell lines or under the dif-
fering conditions. Bottom Panel: Equivalent amounts of the same samples loaded on traditional SDS-PAGE and probed for 
GAPDH as a loading control. C. Increases in expression of SHH and Gli-1 mRNA upon serum starvation. RealTime PCR analy-
sis of SHH (black bars) and GLI1 (grey bars) as increased fold change compared to normal growth conditions. Gene expression 
determined by All Real Time PCR with an n = 9 and normalized to Beta-actin. Error bars indicate standard deviation.
Molecular Cancer 2006, 5:9 http://www.molecular-cancer.com/content/5/1/9sequential slides from tissue microarrays we compared the
staining patterns for Perlecan and Sonic Hedgehog (Fig-
ures 3A–3C). Co-localization of Perlecan and Sonic
Hedgehog staining was noted in a significant number of
tumors, while luminal Sonic Hedgehog was not observed
in normal prostate controls. In addition, co-localization
of both Perlecan and Sonic Hedgehog correlated with
increased tumor cell proliferation as shown by Ki-67
(PCNA) staining (Figure 3D). Our previous studies [7]
had examined expression of SHH pathway genes in six
matched benign and tumor patient samples where we
have also examined Perlecan mRNA or protein expression
(Figure 1G, 1H). In four common samples where we
observe up-regulation of Perlecan in tumor tissue, we pre-
viously detected up-regulation of SHH, PTCH1 and GLI1
(patients 945, 1854, 921 and 1866) suggesting a complete
functional pathway in these tumors. In two common sam-
ples where we observe decreased Perlecan mRNA levels, we
previously saw decreased SHH expression (patients 829
and 887). Thus in individual patients, tumor expression
of Perlecan and SHH are correlated, in agreement with the
co-localization of Perlecan and SHH in tissue microarrays.
Inhibition of Perlecan blocks Sonic Hedgehog signaling in 
cancer cells
To investigate whether Perlecan is directly involved in
modulating SHH signaling we examined the effect of Per-
lecan siRNA on expression of PTCH1 and GLI1, transcrip-
tional targets of the SHH-GLI pathway [18] in LNCaP
cells. Real-Time PCR analysis of Perlecan siRNA treated
cells revealed the expected 80% decrease in Perlecan RNA,
along with an 80% decrease in the level of PTCH1 expres-
sion and a 90% decrease in GLI1expression compared to
controls (Figure 4A). A similar decrease in Perlecan pro-
tein levels in Perlecan siRNA treated LNCaP cells com-
pared to control siRNA was noted (data not shown).
These results demonstrate that Perlecan is required in
androgen sensitive prostate cancer cells to achieve maxi-
mal SHH signaling activity.
Given that Perlecan has been shown to modulate the sig-
naling of multiple growth factors including FGF2, FGF10
and VEGF, we asked if the reduction of prostate cancer cell
growth in Perlecan siRNA treated cells was a result of
decreased SHH signaling. If the decreased BrdU incorpo-
ration was due to inhibition of SHH signaling, then
expression of the SHH downstream effector GLI1 should
rescue the effects of Perlecan siRNA treatment. LNCaP
cells were simultaneously transfected with Perlecan siRNA
and an expression vector for GLI1 and their proliferation
compared to that of controls transfected only with Perle-
can siRNA (Figure 4B). As we observed earlier, transfec-
tion of Perlecan siRNA alone resulted in a drop in BrdU
incorporation compared to controls. When Perlecan RNAi
and the GLI1 expression vector were co-transfected, the
percentage of BrdU labeling returned to control levels.
Transfection of the GLI1 expression vector alone did not
appreciably change LNCaP cell proliferation. This demon-
strates that the major role of Perlecan in LNCaP cells is to
maintain levels of SHH signaling.
Perlecan forms a complex with Sonic Hedgehog
Finally, we asked how Perlecan might affect signaling by
SHH. Previously, we had demonstrated that Perlecan
from flies or mice forms a complex with Hedgehog [5]. To
test for a tumor cell complex containing both Perlecan
and SHH we performed co-immunoprecipitation studies
from the LNCaP series (Figure 4C). Perlecan-SHH com-
plexes were detected in the conditioned medium of all cell
lines under normal growth conditions. The mature Sonic
Hedgehog protein was identified by Western blotting in
all protein extracts precipitated with anti-Perlecan anti-
bodies but not from extracts precipitated with control
antibodies. Increased amounts of SHH-Perlecan com-
plexes were detected in C4-2 and C4-2B, the two meta-
static cell lines. The level of Perlecan protein does not
change appreciably in the LNCaP series (Figure 5B), while
the levels of SHH mRNA decrease across the series with
increasing metastatic potential (Figure 4D). The presence
of higher levels of SHH bound to Perlecan in the C4-2 and
C4-2B cells when the levels of Perlecan protein are similar
across the cell lines suggests increased binding of SHH to
the available Perlecan. The increased amount of bound
SHH is apparently functional, as Real-Time PCR studies
indicate a relative increase in PTCH1 expression with
respect to SHH in C4-2 and C4-2B when compared to
LNCaP (Figure 4D). Taken together, the results of our
expression, inhibition, and biochemical studies link Perle-
can expression and function to SHH-GLI pathway activity
in advanced prostate cancer cells.
Tumor cells maintain Perlecan under poor androgen/
growth factor conditions
The LNCaP series showed a large decrease in BrdU incor-
poration in response to Perlecan siRNA, indicating Perle-
can based growth dependence under normal conditions
regardless of their tumorigenic or metastatic potential.
Our tissue microarray studies showed a correlation
between Perlecan/SHH co-localization and both higher
Gleason grade and stronger Ki-67 staining, suggesting that
more aggressive or metastatic cells are more likely to use
Perlecan-mediated SHH signaling. Since rapidly growing
tumors tend to create microenvironments depleted of
growth factors we asked if growth factor/androgen deple-
tion via serum starvation would trigger the upregulation
of Perlecan in an effort to more effectively use limiting
growth factors such as SHH. In the parental LNCaP cell
line, Perlecan mRNA levels decreased upon serum starva-
tion (Figure 5A). However, the androgen insensitive C4,
C4-2 and C4-2B lines maintained or increased their levelsPage 9 of 15
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ting for Perlecan protein confirms these results for the cell
lines under normal and serum starvation conditions (Fig-
ure 5B). We then asked if the expression of Perlecan in
more metastatic lines under poor growth conditions cor-
related with SHH signaling activity. Real-Time PCR analy-
sis for mRNA expression of SHH and the SHH response
gene GLI1 upon starvation (Figure 5C) demonstrated that
while expression of both SHH and GLI1 dropped in the
LNCaP cell line, expression of both genes increased in the
more tumorigenic and metastatic cell lines. Thus the level
of GLI1 expression correlates with changes in Perlecan
expression upon serum starvation in the LNCaP series
(Figure 5A). This suggests that tumor cells such as C4, C4-
2 and C4-2B that are capable of forming tumors and/or
metastasizing without stromal support maintain a high
level of SHH signaling under adverse growth conditions
by maintaining high levels of Perlecan and SHH expres-
sion.
Discussion
Perlecan, a candidate oncogene for the CAPB locus
Using a bioinformatics based approach we identified Per-
lecan as a candidate oncogene involved in both prostate
cancer and glioblastoma multiforme based on its genetic
association with the CAPB locus at 1p36. Here we demon-
strate Perlecan's expression and functional role in prostate
cancer, and link it to the Sonic Hedgehog pathway known
to be involved in glial tumorigenesis [19]. Thus from
genetic mapping, physiological, and expression data there
is evidence to suggest that Perlecan is a strong candidate
for the CAPB oncogene. The results of interference with
Perlecan function demonstrate that this proteoglycan is
required for the growth of prostate cancer cells, extending
its previously described roles in melanoma, colon, and
lung cancer [20-22] and emphasizing Perlecan's role in
multiple tumor types. Of note, genetic mapping studies
have also identified a link between familial melanoma
and 1p36, providing another link between Perlecan and
tumorigenesis [23].
Perlecan's regulation of growth factors and the link to 
Sonic Hedgehog
As Perlecan has been shown to bind a variety of growth
factors in different tumors, the question as to which
growth factor is being modulated in prostate cancer arose.
Sonic Hedgehog has been associated with brain tumors
and melanomas, two tumors with known genetic links to
1p36, where Perlecan is located [3,23]. Sonic Hedgehog
has recently been linked to prostate cancer through a vari-
ety of studies [6]. We have demonstrated an increased fre-
quency of Sonic Hedgehog positivity in prostate cancer
tissue microarrays, and that Sonic Hedgehog signaling
regulates tumor cell growth in both primary prostate
tumor samples and prostate cancer cell lines [7]. High lev-
els of Sonic Hedgehog activity, as monitored by PTCH1,
GLI1 or HIP expression, are present in all metastatic pros-
tate cancer samples that have been tested [8,9]. In fact,
high levels of PTCH1 and HIP expression correlate with
high (8–10) Gleason scores [8] where we have observed
Perlecan expression. Furthermore, activation of the Sonic
Hedgehog pathway by expression of Gli in the low meta-
static potential rat AT2.1 cell line produced highly meta-
static behavior, suggesting that high level activation of the
Sonic Hedgehog pathway determines metastatic behavior
[9]. Finally, Sonic Hedgehog promotes the growth of
LNCaP derived xenograft tumors in mice [17]. We exam-
ined the potential of Perlecan to regulate Sonic Hedgehog
signaling in tumors. The importance of heparan sulfate
proteoglycans for Sonic Hedgehog signaling has been
demonstrated in neural development, as mutations in the
heparan sulfate binding site on Sonic Hedgehog causes
decreased Sonic Hedgehog-driven proliferation [24]. In
Drosophila, mutations in either Perlecan, or heparan sul-
fate synthesis or modification genes, greatly perturb
Hedgehog signaling efficiency by affecting Hedgehog
transport and binding [5,25-27]. Here we extend these
findings in development to neoplasia by demonstrating
that Sonic Hedgehog both co-localizes and directly binds
to Perlecan in tumors, and that Sonic Hedgehog signaling
occurs through Perlecan. This links Perlecan to the Sonic
Hedgehog-Patched-Gli signaling pathway involved in
prostate cancer [6], where Perlecan acts to modulate the
effects of Sonic Hedgehog. As the Sonic Hedgehog signal-
ing pathway has been linked to multiple tumor types
including prostate, stomach, brain, and skin tumors [6]
this evidence suggests a more general role for Perlecan in
tumor regulation and tumorigenesis. We have surveyed a
variety of tumor types and found SHH and Perlecan co-
localization in a number of these, such as squamous cell
carcinomas and adenocarcinomas of various origins
along with tumors deriving from areas of normal Perlecan
expression such as chondrosarcomas and osteosarcomas
(data not shown).
Perlecan in familial versus sporadic prostate cancers
We have demonstrated a positive correlation between Per-
lecan immunostaining and prostate tumors, in particular
for high Gleason score tumors (Table 1). While genetic
mapping studies make Perlecan an excellent candidate for
the CAPB oncogene, our clinical validation has been per-
formed on prostate samples without information regard-
ing their familial prostate cancer history. Due to the rarity
of families with familial brain and prostate tumors, it is
most likely that the tumors studied do not represent CAPB
kindreds. The suggested role of Perlecan in up-regulating
Sonic Hedgehog signaling in sporadic prostate tumors,
combined with its association with a prostate cancer
genetic susceptibility locus, places Perlecan among a small
group of genes with links to both familial and sporadicPage 10 of 15
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can is part of a common oncogenesis pathway that both
familial and sporadic tumors may traverse during onco-
genesis. Of note, other members of the Sonic Hedgehog
pathway, namely SU(FU), GLI1 and SMOH also map to
areas implicated in familial genetic studies (reviewed in
[6]) and are up-regulated in studies of sporadic prostate
cancer tumors [7-9]. Thus combining genetic analyses
with evaluation of spontaneous tumors may allow us to
identify the common pathways for carcinogenesis.
Perlecan's role in prostate tumor growth: selective growth 
advantage for aggressive tumor cells under low androgen 
and/or growth factor conditions
High levels of Perlecan protein correlate significantly with
aggressive, highly proliferating prostate tumors in our tis-
sue microarrays and are also up-regulated in aggressive
tumors from individual patients. Yet Perlecan is not
present or overexpressed in every tumor or even in every
metastatic site of tumor spread. While this result is not
surprising considering the heterogeneity of neoplasia, it
Modulation of androgen and Perlecan regulated Sonic Hedgehog signalingFigure 6
Modulation of androgen and Perlecan regulated Sonic Hedgehog signaling. As changes occur to the tumor microen-
vironment, prostate cancer cells modulate their use of both androgen and Perlecan mediated Sonic Hedgehog signaling. The 
use of androgen (T) occurs via the androgen receptor (AR). Perlecan (P) is produced, binds Sonic Hedgehog (S) and signals 
through the Gli (G) proteins. The heaviness of each arrow indicates relative signaling strength (gene expression, complex for-
mation). Androgen sensitive cells (LNCaP) utilize both androgen and Perlecan-SHH signaling under normal conditions, but 
decrease Perlecan-SHH signaling under poor growth conditions. In contrast aggressive androgen insensitive cells (C4, C4-2, 
C4-2B) utilize both pathways, and upregulate the Perlecan-SHH signaling under poor growth conditions. This may occur 
through increased SHH binding affinity to Perlecan.Page 11 of 15
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signaling in specific situations. This correlation is demon-
strated in the varied responses of the LNCaP-derived pros-
tate cancer cell lines under poor growth conditions. In
these situations Perlecan expression is maintained in the
C4, C4-2, and C4-2B cell lines capable of forming stroma-
independent tumors while the LNCaP parental line
requires stromal support to form tumors and cannot
maintain the Perlecan specific growth advantage [16].
This trait suggests a survival benefit to the more tumori-
genic and metastatic tumor cells. Under poor growth con-
ditions where low androgen and growth factor
concentrations are present, the increased presence of Per-
lecan and its ability to concentrate growth factors would
provide a survival advantage for tumor cells until a more
suitable microenvironment can be found. In fact, our
studies show that relative up-regulation of Perlecan
expression by the more metastatic lines during serum star-
vation allowed them to maintain their levels of SHH stim-
ulation, while the relative down-regulation of Perlecan
expression in LNCaP resulted in decreased SHH signaling
activity. Even under normal growth conditions, the more
metastatic cell lines were able to form more Perlecan-SHH
complexes and obtain greater SHH stimulation. Thus in
the changing tumor microenvironment the more meta-
static tumor cells have a choice of pathways (androgen,
Perlecan-SHH) that can be modified or modulated to
maintain tumor growth.
Heparan sulfate proteoglycans such as Perlecan have been
shown to bind growth factors and may act as reservoirs or
co-receptors for many growth factors [4]. Thus increasing
Perlecan levels under growth factor limiting conditions
such as within an inadequately vascularized tumor would
be beneficial to a tumor cell. We propose that Perlecan
may sustain the growth of nutrient starved prostate cancer
cells in rapidly spreading tumors by amplifying their sen-
sitivity and response to SHH signaling. These findings are
summarized in a model of Perlecan action (Figure 6); in
microenvironments with decreased growth factors and
androgen, such as those encountered by rapidly growing
tumors, Perlecan provides a secondary pathway for
growth through SHH. This is used in both the androgen
responsive and androgen insensitive aggressive tumor
cells. Based on this model, one would hypothesize that
chemotherapeutic treatments that simultaneously target
both the androgen and the Perlecan-mediated Sonic
Hedgehog pathways would provide the best control of
androgen sensitive aggressive prostate cancer.
Perlecan as a global regulator of growth factor action
While we have demonstrated that Sonic Hedgehog is crit-
ical to Perlecan-dependent cancer cell growth, other
growth factors may also be regulated through Perlecan at
different times or in different clinical stages. Recent results
[13] suggest that Perlecan may regulate the activity of dif-
ferent growth factors during metastasis to bone. Thus the
true role of Perlecan may not be regulating a single growth
factor, but its ability to allow the tumor cell to adapt to
differing tumor microenvironments by facilitating the sig-
naling of different growth factors. If this is shown to be
true, Perlecan may be an excellent target for drug target-
ing, with tumor specific targeting achieved through the
selective blocking of specific growth factor binding sites
on Perlecan.
Perlecan function in metastasis, a role in the bony matrix
Perlecan is secreted by tumor cells, but is also present in
specific stromal microenvironments in the body. This
may affect a tumor's propensity to spread to specific sites.
We have shown here that prostate cancer maintains Perle-
can expression when it spreads to the lung or liver, but is
less likely to do this in the soft tissue or lymph nodes.
Maintaining or finding "Perlecan rich" sites may explain
the propensity of tumors to home to specific sites during
metastatic spread. A specific example of a Perlecan rich
site would be the bone extracellular matrix, a major site
for prostate cancer metastasis. In these sites Perlecan plays
a role in normal bone formation and regulation through
the modulation of growth factors utilized by osteoblasts
[28-30]. Recent studies using the bone-targeted prostate
cancer line C4-2B show that Perlecan is required for devel-
opment of metastases through the modulation of growth
factors, and leads to efficient tumor growth and vascular-
ization [13]. Thus it appears that the presence of Perlecan
in the bony matrix may help explain the tropism of pros-
tate cancer to the bony matrix. Use of Perlecan as a drug
target may prove advantageous by blocking bone metasta-
sis and its associated morbidity. Lastly, Perlecan, as a
secreted protein, may prove to be a useful biomarker for
metastatic prostate cancer as well as a marker of either the
risk or detection of tumor metastasis to bone since it can
be easily detected in urine or serum samples, respectively.
Methods
Bioinformatics based analysis for candidate genes in the 
CAPB region
The 1p36 region, as defined by the chromosomal basepair
data present in the human genome build 16 from the
UCSC Genome Browser datasets, was searched for defined
genes as identified in the NCBI LocusLink database. This
search identified 5,108 expressed exons comprising 659
identified transcripts and 619 defined genes. Using text
mining we searched a dataset of 3,737 prostate cancer
genes as defined by co-localization of the gene name
based on a hand annotated list from LocusLink and the
words "prostate cancer" in MEDLINE. From this dataset
14 genes in the 1p36 region had been described in pros-
tate cancer studies. A second text mining search we identi-
fied 15 genes in the CAPB region that also had beenPage 12 of 15
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brain or prostate cancer text mining datasets were com-
mon. We then focused our examination on CAPB region
genes with associated data in brain studies, and prostate
and prostate cancer expression data from the Cancer
Genome Anatomy Project (CGAP) along with cDNA
microarray expression data generated in our laboratory for
the prostate cancer cell lines LNCaP, DU-145, and PC3. A
comparison of these datasets revealed three genes,
EPHA2, HSGP2, and CAP2B, with data in both brain
research studies and expression in the prostate cancer or
the precancerous change high grade prostatic intraepithe-
lial neoplasia. Of these three genes, HSPG2 also was con-
tained within our prostate cancer cell line cDNA
expression datasets, with increased levels of expression in
the derived invasive sublines of PC3 when compared to a
derived non-invasive subline.
Prostate samples and tissue culture
LNCaP, PC3 and DU-145 cell lines were obtained from
ATCC and grown under standard conditions. The LNCaP
series LNCaP, C4, C4-2 and C4-2B were obtained from
Dr. L. Chung. All primary prostate tumors were obtained
by MWD using approved protocols with informed con-
sent on the part of the subjects.
Real Time PCR on cell line RNA samples
Total RNA isolated from cell lines using Trizol and then
further purified using the RiboPure kit (Ambion). Purified
RNA was digested with DNAse (Invitrogen), and analyzed
using the SYBER Green system according to manufacturers
protocols (Applied Biosystems) on an ABI Prism 7700
machine. Each sample was run in triplicate at three differ-
ent concentrations. Primers were designed using Primer
Express software and are available upon request. Fold
increase/decrease comparisons were calculated using the
delta-delta CT method.
Tissue microarray and immunohistochemistry
Upon institutional review board approval, a tissue micro-
array was prepared from 288 radical prostatectomy cases
present at the Medical College of Wisconsin. A second tis-
sue microarray was prepared from samples collected
under approved protocols at the University of Pittsburgh
Medical Center. 0.6 mm cores were arrayed and 5 um sec-
tions processed. Benign tissue, high-grade prostatic
intraepithelial neoplasia, or invasive tumor tissue were
identified by MWD or RD by high molecular weight
cytokeratin staining (CK903 Ab, DAKO). A third tissue
microarray was prepared from samples collected under
approved protocols as part of the rapid autopsy program
at the University of Michigan. For microarray samples, a
common antigen retrieval procedure was carried out.
Slides were processed for Perlecan or SHH and developed
with HRP conjugated secondary antibodies and DAB sub-
strate. For a portion of the tissue microarray anonymous
de-identified pathologic and outcomes data were availa-
ble. Individual cores were examined as duplicates and
staining correlated using Chi-squared, Fisher's Exact or
two-tailed ANOVA analyses.
Transfection and proliferation assays
Purified and desalted siRNAs were purchased from
Ambion as a proprietary non-validated Perlecan siRNA
and a scrambled siRNA control. SiRNA and GLI1 expres-
sion vector transfections were carried out with Lipo-
fectamine 2000 (Invitrogen) as described by the
manufacturer and effects measured after 72 hours. Caso-
dex was used in cell cultures as described previously.
Immunocytochemistry on cell lines was carried out using
with anti-BrdU (Research Diagnostics or Becton-Dickin-
son) and HRP-conjugated secondary antibodies (Boe-
hringer Mannheim) using standard techniques.
Protein extracts, Western blotting and 
immunoprecipitations
Normal and tumor tissue from the same patients were
obtained as described below following approved proto-
cols. Sections were assessed pathologically by a urologic
pathologist (MWD) to determine areas of normal and
tumor tissue. Samples were microdissected and total pro-
tein isolated. Proteins were also isolated from cultured
medium from cell lines grown under normal or serum
starved conditions. Proteins were run on a 1.6% agarose
gel, blotted and probed for Perlecan (Chemicon). Equal
samples were loaded onto a standard SDS-PAGE gel, blot-
ted and probed for GAPDH (Santa Cruz) as a loading con-
trol. Equal amounts of conditioned medium from
equivalently confluent cell lines were immunoprecipi-
tated with an anti- Perlecan or unrelated control antibody,
the resulting complex run on denaturing SDS-PAGE, and
the presence of SHH verified by immunoblotting (Santa
Cruz).
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